Sorted By:

Relevance


Beneficiaries Have Choice of Plans

Chartpack  |  From Our Network

Three-fourths of Part D beneficiaries indicate that having a variety of plans to choose from is important to them....
http://chartpack.phrma.org/programs-chartpack/medicines-in-medicare/beneficiaries-have-choice-of-plans

Improved Adherence for Parkinson’s Patients Linked With Reduced Health Care Utilization and Expenditures

Chartpack  |  From Our Network

Higher adherence to antiparkinson therapy and longer duration of use were associated with lower health care utilization and expenditures for Part D enrollees with Parkinson’s disease. ...
http://chartpack.phrma.org/programs-chartpack/medicines-in-medicare/improved-adherence-for-parkinson-s-patients-linked-with-reduced-health-care-utilization-and-expenditures

Robert Zirkelbach Named PhRMA Executive Vice President

PhRMA  |  Press Release

In this capacity, he was the national spokesman for the health insurance industry and played a lead role in crafting the association’s communications strategy and public policy positioning throughout the health care reform debate and implementation of the Affordable Care Act.
https://www.phrma.org/press-release/robert-zirkelbach-named-phrma-executive-vice-president

Average Price Growth in Medicare Part B Is Less Than Medical Inflation

Chartpack  |  From Our Network

While the Consumer Price Index for medical care has increased since 2006, the volume weighted Average Sales Price for Medicare Part B drugs has remained essentially flat....
http://chartpack.phrma.org/programs-chartpack/medicines-in-medicare/average-price-growth-in-medicare-part-b-is-less-than-medical-inflation

Initial Medicaid Costs for Medicines Greatly Overstate Costs Net of Rebates

Chartpack  |  From Our Network

On average, about 60% of the initial cost of brand medicines is returned to states through rebates. ...
http://chartpack.phrma.org/programs-chartpack/medicines-in-medicaid/initial-medicaid-costs-for-medicines-greatly-overstate-costs-net-of-rebates

Four out of Five Part D Prescriptions Are Generic

Chartpack  |  From Our Network

Since Part D’s inception, generic utilization has steadily increased to 84% in 2013....
http://chartpack.phrma.org/programs-chartpack/medicines-in-medicare/four-out-of-five-part-d-prescriptions-are-generic

Total Part B Drug Costs Have Been Relatively Stable

Chartpack  |  From Our Network

The annual total cost for drugs under the Medicare Part B program has shown little increase since 2006....
http://chartpack.phrma.org/programs-chartpack/medicines-in-medicare/total-part-b-drug-costs-have-been-relatively-stable

Restrictive State Medicaid Preferred Drug Lists May Reduce Adherence and Lead to Poor Outcomes

Chartpack  |  From Our Network

In Alabama, 51% of patients discontinued statin therapy after preferred drug list (PDL) restrictions were imposed, compared to 39% in the previous period....
http://chartpack.phrma.org/programs-chartpack/medicines-in-medicaid/restrictive-state-medicaid-preferred-drug-lists-may-reduce-adherence-and-lead-to-poor-outcomes

Disproportionate Share Hospitals Are Driving Current Volume and Future Program Growth

Chartpack  |  From Our Network

Disproportionate Share Hospitals drive 81% of 340B sales volume but only make up 9% of 340B entities....
http://chartpack.phrma.org/programs-chartpack/medicines-in-340b/disproportionate-share-hospitals-are-driving-current-volume-and-future-program-growth

Without Significant Reforms 340B Will Continue to Grow As Uninsured Rate Declines

Chartpack  |  From Our Network

340B policies and structure require fundamental reform....
http://chartpack.phrma.org/programs-chartpack/medicines-in-340b/without-significant-reforms-340b-will-continue-to-grow-as-uninsured-rate-declines

Part B Medicines Represent Significant Medical Advances

Chartpack  |  From Our Network

Part B medicines have yielded breakthroughs in cancer, arthritis and autoimmune diseases like lupus....
http://chartpack.phrma.org/programs-chartpack/medicines-in-medicare/part-b-medicines-represent-significant-medical-advances

Better Use of Medicines Yields Significant Health Gains and Savings on Other Services

Chartpack  |  From Our Network

Due to a growing body of evidence, in 2012 the Congressional Budget Office (CBO) began recognizing reductions in other medical expenditures associated with increased use of prescription medicines in Medicare....
http://chartpack.phrma.org/biophrma-chartpack/outcomes-and-savings/better-use-of-medicines-yields-significant-health-gains-and-savings-on-other-services

Combination of Vague Rules Defining a Patient and Lack of Enforcement Leads to Program Abuse

Chartpack  |  From Our Network

The lack of an appropriate patient definition means hospitals can profit from 340B discounts for patients whose prescriptions should not qualify for 340B....
http://chartpack.phrma.org/programs-chartpack/medicines-in-340b/combination-of-vague-rules-defining-a-patient-and-lack-of-enforcement-leads-to-program-abuse

“Average Manufacturer Price” Is Not the Average Price Received by Manufacturers

Chartpack  |  From Our Network

While originally intended only for use in the rebate calculation, over time AMP has also become a metric for pharmacy reimbursement and has been redefined to reflect the price paid by retail community pharmacies....
http://chartpack.phrma.org/programs-chartpack/medicines-in-medicaid/average-manufacturer-price-is-not-the-average-price-received-by-manufacturers

Part D Share of Medicare Expenditures

Chartpack  |  From Our Network

Medicare Part D drug spending, including brand and generic, made up 10.9% of Medicare spending in 2014....
http://chartpack.phrma.org/programs-chartpack/medicines-in-medicare/part-d-share-of-medicare-expenditures

Part D Improved Health Outcomes, Significantly Reducing Depressive Symptoms Among Seniors

Chartpack  |  From Our Network

A recent study found that the introduction of Part D significantly reduced depressive symptoms among older adults, and that such gains in mental health grew stronger over time....
http://chartpack.phrma.org/programs-chartpack/medicines-in-medicare/part-d-improved-health-outcomes-significantly-reducing-depressive-symptoms-among-seniors

Patients Facing Access Restrictions Incur Greater Medical Spending

Chartpack  |  From Our Network

Non-elderly Medicaid patients facing formulary restrictions for antipsychotic medications were 7% to 13% more likely to be hospitalized and had higher medical costs than patients in states without formulary restrictions....
http://chartpack.phrma.org/programs-chartpack/medicines-in-medicaid/patients-facing-access-restrictions-incur-greater-medical-spending

The US Prescription Drug Lifecycle Generates Savings for Part D

Chartpack  |  From Our Network

The prescription drug lifecycle is projected to save the Part D program $56 billion between 2006 and 2014....
http://chartpack.phrma.org/programs-chartpack/medicines-in-medicare/the-us-prescription-drug-lifecycle-generates-savings-for-part-d

Part B Generally Covers Injected and Infused Medicines Across Several Settings

Chartpack  |  From Our Network

Approximately 600 Part B drugs are administered in various locations....
http://chartpack.phrma.org/programs-chartpack/medicines-in-medicare/part-b-generally-covers-injected-and-infused-medicines-across-several-settings

PhRMA Statement on Report President Commissions’ Final Report with Opioid Recommendations

PhRMA  |  Press Release

“PhRMA is working with the National Institutes of Health (NIH) and National Institute on Drug Abuse (NIDA) to establish a public-private partnership that will advance the development of non-addictive pain treatment options, as well as new treatments for addiction and overdose.
https://www.phrma.org/press-release/phrma-statement-on-report-president-commissions-final-report-with-opioid-recommendations

Improving Adherence Could Yield Additional Savings

Chartpack  |  From Our Network

Improving adherence to congestive heart failure (CHF) medicines could result in federal savings of $22.4 billion over 10 years.   ...
http://chartpack.phrma.org/biophrma-chartpack/outcomes-and-savings/improving-adherence-could-yield-additional-savings

Cardiovascular-Related Mortality Dropped Significantly Following Part D Implementation

Chartpack  |  From Our Network

Mortality rates dropped and years of life lost were reduced significantly in areas most impacted by the implementation of Part D. ...
http://chartpack.phrma.org/programs-chartpack/medicines-in-medicare/cardiovascular-related-mortality-dropped-significantly-following-part-d-implementation

Medicaid Rebates on Prescription Medicines Are Increasing Substantially Under the Affordable Care Act

Chartpack  |  From Our Network

Independent analysts estimate that the Affordable Care Act (ACA) will increase the Medicaid prescription drug rebates brand manufacturers pay....
http://chartpack.phrma.org/programs-chartpack/medicines-in-medicaid/medicaid-rebates-on-prescription-medicines-are-increasing-substantially-under-the-affordable-care-act

Phaseout of Coverage Gap in Part D Began in 2011

Chartpack  |  From Our Network

Beginning in 2011, beneficiaries receive a 50% discount on brand drugs while in the coverage gap, at a cost to brand manufacturers of $41 billion over 10 years (2012-2021)....
http://chartpack.phrma.org/programs-chartpack/medicines-in-medicare/phaseout-of-coverage-gap-in-part-d-began-in-2011

Part D Reduced Costs and Improved Access to Medicines for Beneficiaries Previously Without Coverage and for Disabled Beneficiaries

Chartpack  |  From Our Network

Part D reduced costs and improved access to medicines for beneficiaries. ...
http://chartpack.phrma.org/programs-chartpack/medicines-in-medicare/part-d-reduced-costs-and-improved-access-to-medicines-for-beneficiaries-previously-without-coverage-and-for-disabled-beneficiaries

You have reviewed the first 100 results out of 882. Each page contains 25 results. You're on page 4.

prev 1 2 3 4 5 6 next